Literature DB >> 17386990

Factors associated with one step surgery in case of non-palpable breast cancer.

Fritz K Schaefer1, I Eden, P J Schaefer, D Peter, W Jonat, M Heller, I Schreer.   

Abstract

PURPOSE: To examine factors associated with one step surgery in case of non-palpable breast cancer.
MATERIALS AND METHODS: Clinical data of 152 consecutively diagnosed patients with breast cancer were analyzed retrospectively. Preoperative diagnostic findings were divided in subgroups: mammographically visible mass/microcalcifications/sonographically visible mass/sonographically visible architectural distortion. Correlation between tumor-size, radiologic tumor morphology, quality of localization and number of operation was evulated. For localization exact wire position was defined less than 3mm apart from the lesion.
RESULTS: One hundred and thirty-six patients attempted breast conservation and underwent preoperative tumor localization. Fourteen of 16 patients had mastectomy without preoperative localization. Average tumor size was 12mm for one-operation, and 17mm for re-operation. Significant correlation (p<0.001) was found between one operation and masses visible in mammograms (55/62 (89%) patients) or sonography (53/64 (83%) patients). Significant correlation was found (p<0.001) between more re-operation and microcalcifications in mammograms (33/89 (37% patients). In 123/138 (89%) cases wire position was central, in 15/138 (11%) cases distance was maximally 10mm. No significant correlation was found between number of operation and wire position. Re-operation was required in 38 cases.
CONCLUSION: Mammographically or sonographically visible mass, small size of tumors, preoperative percutaneous biopsy and exact preoperative localization are important for a single step procedure for definite surgical treatment, that we found in 74% of the patients.

Entities:  

Mesh:

Year:  2007        PMID: 17386990     DOI: 10.1016/j.ejrad.2007.02.033

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  6 in total

1.  Sonographic tomography for the preoperative staging of breast cancer prior to surgery.

Authors:  I Grady; H Gorsuch-Rafferty; P Hansen
Journal:  J Ultrasound       Date:  2010-07-24

2.  Contrast-enhanced spectral mammography vs. mammography and MRI - clinical performance in a multi-reader evaluation.

Authors:  Eva M Fallenberg; Florian F Schmitzberger; Heba Amer; Barbara Ingold-Heppner; Corinne Balleyguier; Felix Diekmann; Florian Engelken; Ritse M Mann; Diane M Renz; Ulrich Bick; Bernd Hamm; Clarisse Dromain
Journal:  Eur Radiol       Date:  2016-11-28       Impact factor: 5.315

3.  Radioguided occult lesion localisation versus wire-guided lumpectomy in the treatment of non-palpable breast lesions.

Authors:  Tibor Takács; Attila Paszt; Zsolt Simonka; Szabolcs Abrahám; Bernadett Borda; Aurél Ottlakán; Katalin Ormándi; Máté Lázár; András Vörös; Zsuzsanna Kahán; Gyorgy Lazar
Journal:  Pathol Oncol Res       Date:  2012-10-14       Impact factor: 3.201

4.  Tracking nonpalpable breast cancer for breast-conserving surgery with carbon nanoparticles: implication in tumor location and lymph node dissection.

Authors:  Yanyan Jiang; Nan Lin; Sheng Huang; Chongping Lin; Na Jin; Zaizhong Zhang; Jun Ke; Yinghao Yu; Jianping Zhu; Yu Wang
Journal:  Medicine (Baltimore)       Date:  2015-03       Impact factor: 1.889

5.  Analysis of Diagnostic Methods for Focal Lesions in Breast Glands with Use of Open Surgical Biopsies and Core-Needle Biopsies in Poland.

Authors:  Andrzej Lorek; Andrzej Śliwczyński; Barbara Więckowska; Bartosz Stawowski; Janusz Dagiel; Jacek Gawrychowski
Journal:  Med Sci Monit       Date:  2018-07-17

6.  Clinical performance of contrast-enhanced spectral mammography in pre-surgical evaluation of breast malignant lesions in dense breasts: a single center study.

Authors:  Anna Bozzini; Luca Nicosia; Giancarlo Pruneri; Patrick Maisonneuve; Lorenza Meneghetti; Giuseppe Renne; Andrea Vingiani; Enrico Cassano; Mauro Giuseppe Mastropasqua
Journal:  Breast Cancer Res Treat       Date:  2020-08-28       Impact factor: 4.872

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.